Yong Shan

Yong Shan

Auto-generated profile, based on publicly available information

Yong Shan

Department of Biostatistics and Data Science, The University of Texas Medical Branch, Galveston, TX 77555, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
BHByron Hughes
Byron Hughes
CCClaire B. Cummins
Claire B. Cummins
YSYong Shan
Yong Shan
HMHemalkumar B. Mehta
Hemalkumar B. Mehta
RRRavi Radhakrishnan
Ravi Radhakrishnan
KBKanika A. Bowen-Jallow
Kanika A. Bowen-Jallow

10 April 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
VAVictor Adekanmbi
Victor Adekanmbi
Fangjian GuoFangjian Guo
Fangjian Guo
CHChristine D. Hsu
Christine D. Hsu
YSYong Shan
Yong Shan
YKYong_Fang Kuo
Yong_Fang Kuo
ABAbbey Berenson
Abbey Berenson
Background: In the United States, the human papillomavirus (HPV) vaccine is approved for use in individuals up to age 45. Individuals 15 years and older require three doses of the vaccine to complete the recommended dosing series. Incomplete HPV vaccination rates (i.e., one or two doses) among those over age 26, however, remain high. This study examined the independent effects of individual- and neighborhood-level factors on incomplete HPV vaccination rates in the United States (U.S.) among those aged 27–45 years. Methods: This retrospective cohort study used administrative data from Optum’s de-identified Clinformatics® Data Mart Database to identify individuals aged 27–45 years who received one or more doses of HPV vaccine between July 2019 and June 2022. Multilevel multivariable logistic regression models were applied to the data on 7662 individuals identified as being fully or partially vaccinated against HPV, nested within 3839 neighborhoods across the U.S. Results: Approximately half of the patients in this study (52.93%) were not completely vaccinated against HPV. After adjusting for all other covariates in the final model, being older than 30 years old decreased the odds of not completing the HPV vaccine series. Participants living in South-region neighborhoods of the U.S. had enhanced odds of not completing the vaccine series compared with those residing in Northeast-region neighborhoods (aOR 1.21; 95% CrI 1.03–1.42). There was significant clustering of incomplete HPV vaccination rates at the neighborhood level. Conclusions: This study revealed that individual- and neighborhood-level factors were associated with the risk of not completing the HPV vaccine series among individuals aged 27–45 years in the U.S. Interventions to improve HPV vaccination series completion rates for this age group should take into consideration both individual and contextual factors.